ATE528013T1 - Impfstoff-zusammensetzungen - Google Patents
Impfstoff-zusammensetzungenInfo
- Publication number
- ATE528013T1 ATE528013T1 AT09706841T AT09706841T ATE528013T1 AT E528013 T1 ATE528013 T1 AT E528013T1 AT 09706841 T AT09706841 T AT 09706841T AT 09706841 T AT09706841 T AT 09706841T AT E528013 T1 ATE528013 T1 AT E528013T1
- Authority
- AT
- Austria
- Prior art keywords
- vaccine compositions
- treatment
- relates
- hypercytokines
- melanoma
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2008/000780 WO2009095033A1 (en) | 2008-01-31 | 2008-01-31 | Vaccine compositons |
| PCT/EP2009/000626 WO2009095261A2 (en) | 2008-01-31 | 2009-01-30 | Vaccine compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE528013T1 true ATE528013T1 (de) | 2011-10-15 |
Family
ID=39264516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT09706841T ATE528013T1 (de) | 2008-01-31 | 2009-01-30 | Impfstoff-zusammensetzungen |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20110002898A1 (de) |
| EP (1) | EP2252322B1 (de) |
| JP (1) | JP2011511772A (de) |
| CN (1) | CN101965194A (de) |
| AT (1) | ATE528013T1 (de) |
| AU (1) | AU2009210204A1 (de) |
| CA (1) | CA2714554A1 (de) |
| DK (1) | DK2252322T3 (de) |
| IL (1) | IL207310A (de) |
| WO (2) | WO2009095033A1 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0634460A2 (de) | 1993-07-13 | 1995-01-18 | ALBRIGHT & WILSON UK LIMITED | Antikorrosive Pigmente |
| US7972594B2 (en) | 2006-11-13 | 2011-07-05 | Immunovative Therapies Ltd. | Ablative immunotherapy |
| US8664390B2 (en) | 2007-06-29 | 2014-03-04 | Generics (Uk) Limited | Process for the introduction of hydroxyethoxy side chain in bosentan |
| EP2387415A1 (de) * | 2009-01-16 | 2011-11-23 | AGIRx Limited | Impfstoffzusammensetzungen |
| US20160022789A1 (en) * | 2012-08-15 | 2016-01-28 | Neostem Oncology, Llc | Individualized high purity colon carcinoma stem cells, methods and use of the same |
| US20160058855A1 (en) * | 2012-08-15 | 2016-03-03 | Neostem Oncology, Llc | High purity ovarian cancer stem cells for active autologous immune therapy |
| AU2014249344A1 (en) * | 2013-03-11 | 2015-09-10 | Neostem Oncology, Llc | Method of induction and purification of a cell population responsible for vasculary mimicry and use of the same |
| WO2014165103A1 (en) * | 2013-03-12 | 2014-10-09 | California Stem Cell, Inc. | Individualized high-purity glioblastoma multiforme stem cells and methods for stimulating immune response |
| WO2014164396A1 (en) * | 2013-03-12 | 2014-10-09 | Michael Har-Noy | Ablative immunotherapy |
| EP2992898A1 (de) * | 2014-09-04 | 2016-03-09 | Klinikum rechts der Isar der Technischen Universität München | T-Zell-Adjuvant und dessen Verwendung zur therapeutischen und prophylaktischen Impfung |
| KR20190100200A (ko) * | 2016-11-22 | 2019-08-28 | 알로플렉스 바이오테라퓨틱스 | 동종이형 종양 세포 백신 |
| US11320427B2 (en) * | 2017-07-13 | 2022-05-03 | Taipei Medical University | Tandemly repeated antibody-binding protein and its applications |
| EP3875111A1 (de) * | 2020-03-05 | 2021-09-08 | Poznan University Of Medical Sciences | Stammzellkrebsimpfstoffzusammensetzung |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6406689B1 (en) * | 1995-10-03 | 2002-06-18 | Frank W. Falkenberg | Compositions and methods for treatment of tumors and metastatic diseases |
| EP1125133A1 (de) * | 1998-11-03 | 2001-08-22 | Cell Genesys, Inc. | Krebs-assoziierte antigene und verfahren zu ihrer identifizierung |
| WO2003092579A2 (en) * | 2002-04-29 | 2003-11-13 | Hadasit Medical Research Services And Development Company Ltd. | Compositions and methods for treating cancer with an oncolytic viral agent |
| EP1598364A1 (de) * | 2004-05-21 | 2005-11-23 | AGIRx Limited | Chimerischer löslicher Hyper IL-11 Rezeptor und dessen Verwendung |
-
2008
- 2008-01-31 WO PCT/EP2008/000780 patent/WO2009095033A1/en not_active Ceased
-
2009
- 2009-01-30 CN CN2009801072447A patent/CN101965194A/zh active Pending
- 2009-01-30 JP JP2010544642A patent/JP2011511772A/ja active Pending
- 2009-01-30 WO PCT/EP2009/000626 patent/WO2009095261A2/en not_active Ceased
- 2009-01-30 DK DK09706841.5T patent/DK2252322T3/da active
- 2009-01-30 AT AT09706841T patent/ATE528013T1/de active
- 2009-01-30 US US12/865,178 patent/US20110002898A1/en not_active Abandoned
- 2009-01-30 CA CA2714554A patent/CA2714554A1/en not_active Abandoned
- 2009-01-30 EP EP09706841A patent/EP2252322B1/de not_active Not-in-force
- 2009-01-30 AU AU2009210204A patent/AU2009210204A1/en not_active Abandoned
-
2010
- 2010-07-29 IL IL207310A patent/IL207310A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009095261A2 (en) | 2009-08-06 |
| IL207310A (en) | 2016-06-30 |
| CN101965194A (zh) | 2011-02-02 |
| EP2252322B1 (de) | 2011-10-12 |
| AU2009210204A1 (en) | 2009-08-06 |
| JP2011511772A (ja) | 2011-04-14 |
| EP2252322A2 (de) | 2010-11-24 |
| WO2009095261A3 (en) | 2009-09-24 |
| WO2009095033A1 (en) | 2009-08-06 |
| IL207310A0 (en) | 2010-12-30 |
| US20110002898A1 (en) | 2011-01-06 |
| DK2252322T3 (da) | 2012-01-30 |
| CA2714554A1 (en) | 2009-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2252322T3 (da) | Vaccinesammensætninger | |
| MX342274B (es) | Actividades de la piruvato quinasa m2 (pkm2). | |
| TR201907783T4 (tr) | Benzosulfonamit türevleri, bileşimleri ve kanser hücrelerinin metastazının önlenmesinde kullanımları. | |
| EA201590987A1 (ru) | Соединения и способы их применения | |
| EA201101522A1 (ru) | Способы лечения болезней с использованием эпиметаболического переключателя (коэнзим q10) | |
| PH12014501639B1 (en) | Pharmaceutical compositions and methods | |
| MY191825A (en) | Therapeutic compounds and compositions | |
| MX2019000225A (es) | Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades. | |
| IN2015DN02826A (de) | ||
| MX344521B (es) | Aminas heterociclicas y sus usos. | |
| BR112015011756A2 (pt) | inibidores da glutamase e métodos de uso | |
| CU20120078A7 (es) | Composiciones para tratar náusea y vómito centralmente mediados | |
| CR20110553A (es) | Terapia complementaria contra el cáncer | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| EP4582090A3 (de) | Zusammensetzung mit pegylierter arginin-deiminase | |
| MX370721B (es) | Compuestos y composiciones novedosas para atacar las células madre del cáncer. | |
| MX2015001551A (es) | Compuestos y composiciones activadoras de enzima. | |
| FR2945210B1 (fr) | Combinaison antitumorale comprenant l'ave8062 et le sorafenib | |
| EP2597949A4 (de) | Submikrometerzusammensetzungen | |
| GB2528604A (en) | Modulation of asymmetric proliferation | |
| GB2519004A (en) | Quinone compounds and their uses for the treatment of cancer | |
| TN2012000552A1 (en) | An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative | |
| EP2575766A4 (de) | Neue pharmazeutische verbindungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 2252322 Country of ref document: EP |